Future of pharmacogenetics-based therapy for tuberculosis

Pharmacogenomics

Volumn 15, Issue 5, 2014, Pages 601-607

  Matsumoto, Tomoshige ^a   Ohno, Masako ^b   Azuma, Junichi ^b  

^a Department of Medicine Osaka Anti Tuberculosis Association Osaka Hospital   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

drug induced liver injury; isoniazid; latent tuberculosis infection; N acetyltransferase 2; NAT2; personalized medicine; pharmacogenetics; pulmonary tuberculosis

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; ISONIAZID; TUBERCULOSTATIC AGENT;

CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG SAFETY; GENE THERAPY; GENOTYPE; HUMAN; INFECTION PREVENTION; INFECTION RISK; INTERFERON GAMMA RELEASE ASSAY; INTERMETHOD COMPARISON; MULTICENTER STUDY (TOPIC); PERSONALIZED MEDICINE; PHARMACOGENETICS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SPUTUM CULTURE; TREATMENT DURATION; TUBERCULIN TEST; TUBERCULOSIS; DRUG-INDUCED LIVER INJURY; GENETICS; TRENDS;

ANTITUBERCULAR AGENTS; DRUG-INDUCED LIVER INJURY; HUMANS; INDIVIDUALIZED MEDICINE; PHARMACOGENETICS; TUBERCULOSIS;

EID: 84899808918     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.14.38     Document Type: Review

References (32)

1. WHO. Global Health Observatory (GHO); Tuberculosis (TB). www.who.int/gho/tb/en/index.html
2. Blumberg HM, Burman WJ, Friedman LN. et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of tuberculosis. Am. J. Respir. Crit. Care Med. 167(4), 603-662 (2003).
3. The Global Plan to Stop TB Stop TB Partnership. www.stoptb.org/global/ plan
4. WHO guidelines for treatment of tuberculosis, 4th Edition. www.who.int/tb/publications/2010/9789241547833/en
5. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am. J. Respir. Crit. Care Med. 167(11), 1472-1477 (2003).
6. Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin. A meta-Analysis. Chest 99(2), 465-471 (1991).
7. Jindani A, Nunn AJ, Enarson DA. Two 8 month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: International multicentre randomised trial. Lancet 364(9441), 1244-1251 (2004).
8. Durand F, Jebrak G, Pessayre D, Fournier M, Bernuau J. Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status. Drug Saf. 15(6), 394-405 (1996).
9. Manolio TA, Chisholm RL, Ozenberger B. et al. Implementing genomic medicine in the clinic: The future is here. Genet. Med. 15(4), 258-267 (2013).
10. Wang L, McLeod HL, Weinshilboum RM. Genomics and drug response. N. Engl. J. Med. 364(12), 1144-1153 (2011).
11. Evans DA, Manley KA, McKusick VA. Genetic control of isoniazid metabolism in man. Br. Med. J. 2(5197), 485-491 (1960).
12. Evans DA, Storey PB, Wittstadt FB, Manley KA. The determination of the isoniazid inactivator phenotype. Am. Rev. Respir. Dis. 82, 853-861 (1960).
13. Human NAT2 alleles (Haplotypes). Last updated 19/11/2013. The database of arylamine N-Acetyltransferases (NATs). http://nat.mbg.duth.gr/Human%20 NAT2%20alleles-2013.htm
14. Mashimo M, Suzuki T, Abe M, Deguchi T. Molecular genotyping of N-Acetylation polymorphism to predict phenotype. Hum. Genet. 90(1-2), 139-143 (1992).
15. Parkin DP, Vandenplas S, Botha FJ. et al. Trimodality of isoniazid elimination: Phenotype and genotype in patients with tuberculosis. Am. J. Respir. Crit. Care Med. 155(5), 1717-1722 (1997).
16. Mitchell JY, Zimmerman HJ, Ishak KG. et al. Isoniazid liver injury: Clinical spectrum, pathology and probable pathogenesis. Ann. Intern. Med. 84(2), 181-192 (1976).
17. Sarma GR, Immanuel C, Kailasam S, Narayana AS, Venkatesan P. Rifampin induced release of hydrazine from isoniazid: A possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid: A possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid and rifampin. Am. Rev. Respir. Dis. 133(6), 1072-1075 (1986).
18. Ellard GA. Variations between individuals and populations in the acetylation of isoniazid and its significance for the treatment of pulmonary tuberculosis. Clin. Pharmacol. Ther. 19(5 Pt 2), 610-625 (1976).
19. Donald PR, Sirgel FA, Venter A. et al. The influence of human N-Acetyltransferase genotype on the early bactericidal activity of isoniazid. Clin. Infect. Dis. 39(10), 1425-1430 (2004).
20. Kubota R, Ohno M, Yasunaga M, Yokota S, Maekura R, Azuma J. Tentative treatments for tuberculosis based on N-Acetyltransferase gene polymorphism. Jpn J. Ther. Drug Monit. 22(4), 336-340 (2005).
21. Evans DA. N-Acetyltransferase. Pharmacol. Ther. 42(2), 157-234 (1989).
22. Ohno M, Yamaguchi I, Yamamoto I. et al. Slow N-Acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int. J. Tuberc. Lung Dis. 4(3), 256-261 (2000).
23. Huang YS, Chern HD, Su WJ. et al. Polymorphism of the N-Acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 35(4), 883-889 (2002).
24. Wang PY, Xie SY, Hao Q, Zhang C, Jiang BF. NAT2 polymorphisms and susceptibility to anti-Tuberculosis drug-induced liver injury: A meta-Analysis. Int. J. Tuberc. Lung Dis. 16(5), 589-595 (2012).
25. Cai Y, Yi JY, Zhou CH. et al. Pharmacogenetic study of drug-metabolising enzyme polymorphisms on the risk of anti-Tuberculosis drug-induced liver injury: A meta-Analysis. PLoS ONE 7(10), e47769 (2012).
26. Lee SW, Chung SC, Huang HH, Shen X. NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-Tuberculosis drug-induced hepatitis. Int. J. Tuberc. Lung Dis. 14(5), 622-626 (2009).
27. CYP2E1 allele nomenclature. www.cypalleles.ki.se/cyp2e1.htm
28. Azuma J, Ohno M, Kubota R. et al. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6 month four-drug standard treatment of tuberculosis: A randomized controlled trial for pharmacogenetics-based therapy. Eur. J. Clin. Pharmacol. 69(5), 1091-1101 (2013).
29. Kinzig-Schippers M, Tomalik-Scharte D, Jetter A. et al. Should we use N-Acetyltransferase Type 2 genotyping to personalize isoniazid doses? Antimicrob. Agents Chemother. 49(5), 1733-1738 (2005).
30. Kubota R, Ohno M, Hasunuma T, Iijima H, Azuma J. Dose-escalation study of isoniazid in healthy volunteers with the rapid acetylator genotype of arylamine N-Acetyltransferase 2. Eur. J. Clin. Pharmacol. 63(10), 927-933 (2007).
31. Sabbagh A, Darlu P, Crouau-Roy B, Poloni ES. Arylamine N-Acetyltransferase 2 (NAT2) genetic diversity and traditional subsistence: A worldwide population survey. PLoS ONE 6(4), e18507 (2011).
32. CDC (2013) Latent Tuberculosis Infection: A Guide for the Primary Health Care Providers. www.cdc.gov/tb/publications/ltbi/pdf/TargetedLTBI.pdf